Efficacy of pharmacological treatments for Dravet syndrome: Systematic review and network meta-analysis

• Published in: Seizure (London, England) England), 2024-04, Vol.117, p.90-97
• Main Authors: Xia, Dujiang, Zhang, Peng, Chen, Yankun, Liu, Xi, Chen, Yangmei
• Format: Article
• Language: English
• Subjects: Cannabidiol; Dravet syndrome; Drug efficacy; Fenfluramine; Soticlestat; Stiripentol
• ISSN: 1059-1311; 1532-2688
• DOI: 10.1016/j.seizure.2024.02.004

•Stiripentol performs best in reducing convulsive seizure frequency in DS patients.•Fenfluramine performs best in reducing at least 75 % convulsive seizure frequency.•Stiripentol performs best in reducing at least 50 % convulsive seizure frequency.•Stiripentol need further study in reducing at least 75 % convulsive seizure frequency. Numerous anti-seizure medications (ASMs) have been developed to treat Dravet syndrome (DS). This network meta-analysis aimed to comprehensively analyse the efficacy of ASMs in DS patients, especially in non-seizure-free patients after treatment. PubMed, EMBASE, Cochrane Library, and Chinese National Knowledge Infrastructure databases were searched. The treatment efficacy was assessed by the percentage reduction in monthly convulsive seizure frequency (MCSF) from baseline or individuals who achieved at least a 50 % or 75 % reduction from baseline in convulsive seizure frequency (CSF). Six randomised controlled trials with 633 participants and seven regimens based on four add-on ASMs—fenfluramine (FFA), stiripentol (STP), cannabidiol (CBD), and soticlestat—were included. All drug regimens were superior to the placebo at achieving at least 50 % and 75 % reductions in CSF, but only STP, 0.4 mg/kg/d FFA (FFA0.4), and 0.7 mg/kg/d FFA (FFA0.7) reduced MCSF. STP (50 mg/kg/d) had the highest correlation with reducing MCSF and achieving at least a 50 % reduction from baseline in CSF, followed by FFA0.4 and FFA0.7. Soticlestat and CBD may also be effective in reducing seizures in DS patients. STP can be recommended as the first choice among the included drug regimens for reducing seizures in DS patients, while FFA0.4 may be considered the second choice. Other drug regimens can be used as alternative treatments. STP, FFA0.4, and FFA0.7 may consistently present favourable efficacy in most DS patients, while other regimens may present prominent inter-individual variability. Appropriate dose selection and intense monitoring are necessary when treating DS using these drugs.